Two controlled studies to determine efficacy in the @entity1641 were performed with eltenac, a new injectable, non-steroidal anti-inflammatory drug (NSAID). Clinical trials were carried out with a dose rate of 1 mg/kg body weight in a randomized, placebo-controlled, double-blind design to assess therapeutic efficacy in acute inflammatory disorders and in animals with orthopaedic conditions. In a preliminary pharmacokinetic investigation in six @entity1641 mean elimination half-life was 1.7 h after i.v. administration. In the first clinical study, analgesic activity on @entity158 was determined in a total of 64 @entity1641 . @entity158 was assessed using a rating scale. Compared with the placebo treatment, eltenac produced significant @entity158 relief after a single i.v. injection for a period of 24 h. In the second trial the anti-oedematous effect was determined in post-operative wound @entity4 following castration in two groups of 10 colts. After surgery, the @entity1641 received either an injection of 1 mg/kg eltenac or a placebo injection on three consecutive days. @entity4 was assessed by measuring the diameter of the external preputial fold using two methods: callipers and a rating scale of 0 to 3. Additionally, photographs were taken on days 1, 2 and 4. Compared with the placebo treatment, eltenac @entity158 and @entity4 significantly. The effect was maintained for up to 48 h after the last injection.

Eltenac, a new anti-inflammatory and analgesic drug for XXXX : clinical aspects.

@entity4 :: ('MESH:D004487', 'Disease') :: ['swelling', 'Swelling'] @entity1641 :: ('9796', 'Species') :: ['horse', 'horses'] @entity158 :: ('MESH:D010146', 'Disease') :: ['inhibited pain', 'Pain', 'pain', 'pain-related lameness']
@entity1641 :: (9796,Species) :: ['horses']
